Why Pharmaceutical Vial Stoppers Are Made of Butyl Rubber

Look at a vial of an injectable medicine and the rubber stopper is the least interesting-looking part of the package. It is also the part on which the shelf life of the product usually depends. Glass is an essentially perfect barrier and the aluminium crimp is just a clamp; the stopper is the only polymeric, permeable, deformable element in the system — and it therefore defines the container closure integrity of the whole assembly.

Container closure integrity, or CCI, is the umbrella requirement, and it is more demanding than "does not leak." A parenteral closure has to maintain a microbial barrier and a defined headspace environment for the entire labelled shelf life of the product, through shipping, temperature excursions, and repeated handling. Concretely, the material has to deliver several things at once:

• Microbial and gas ingress barrier — Sterility must be maintained across the glass-to-rubber sealing land under the crimp, not merely at the moment of filling
• Oxygen exclusion — Many biologics and small molecules oxidise. Products filled under nitrogen depend on the closure to keep that headspace inert for years
• Moisture control — A freeze-dried cake is hygroscopic. Water vapour permeating through a stopper raises residual moisture and can collapse the cake or degrade the API
• Resealing after penetration — Multi-dose vials are pierced repeatedly. The elastomer has to close behind the needle and maintain the seal
• Coring resistance — The stopper must not shed a fragment into the solution when a needle passes through it
• Chemical and biological compatibility — Whatever migrates out of the rubber ends up in the injection. This is the extractables and leachables question, and it is often the deciding factor
• Process survivability — Washing, depyrogenation, steam autoclaving or gamma irradiation, and for lyophilised products a full freeze-drying cycle at low temperature and deep vacuum

Notice how the freeze-drying case sharpens all of it. A lyophilisation stopper is partially inserted, sits in the chamber at very low temperature under vacuum during the cycle, then is pushed fully home by the shelf at the end. It must stay elastic when cold enough that many elastomers turn glassy, it must not outgas into the chamber, and it must seal reliably at the moment of stoppering. Very few polymer families do all of that. Butyl is the one the pharmaceutical industry converged on decades ago and has not left.

The barrier argument is the same physics that puts butyl inside every tubeless tyre, applied to a much smaller and much more consequential seal. Butyl rubber is a copolymer of isobutylene with a small isoprene fraction, and the polyisobutylene backbone carries two methyl groups on alternating carbons. That crowding restricts chain motion and leaves very little free volume, so oxygen and water vapour dissolve less readily and diffuse far more slowly than in a conventional elastomer.

The extractables story is equally decisive and often less well understood outside the industry. Everything compounded into a rubber — accelerators, activators, antioxidants, fillers, process aids — is a potential leachable in the finished drug product. Butyl's saturated backbone helps here in a structural way: because it needs far less protection against oxidative attack than a highly unsaturated rubber, the formulation can be simpler and carry fewer of the additive classes that create problematic degradation products. Natural rubber, by contrast, brings both a heavier cure package and biological protein content, and it has been progressively displaced from parenteral closures for exactly these reasons.

1. Halobutyl for cure chemistry — As in tyre liners, bromobutyl and chlorobutyl are generally preferred because the halogen site allows cure systems that avoid some of the more problematic accelerator chemistries while keeping the barrier property intact
2. Filler and pigment control — Mineral fillers are selected for purity and consistency, since anything present in the compound can appear in an extractables study
3. Barrier films where needed — Some closures are laminated or coated with a fluoropolymer film on the drug-contact face to reduce migration further for particularly sensitive formulations
4. Documented, controlled formulation — A closure formulation is effectively frozen once qualified. Change control on raw materials is as important as the original selection

Regulatory expectations here are worth stating in general terms only, because the specifics depend on market and product type. Broadly, elastomeric closures for parenteral use are assessed against pharmacopoeial chapters and ISO standards covering physicochemical testing, biological reactivity, functional properties such as penetrability and fragmentation, and container closure integrity. The point for a materials audience is that qualification is a property of a specific closure design made from a specific, controlled formulation by a qualified converter — never of "butyl rubber" as a generic material.

Garmy manufactures butyl compound for industrial sealing, waterproofing, and NVH applications. We do not produce pharmaceutical closures, but the barrier mechanism described above is the same one our compounds are formulated around.

Understanding why butyl works is only half the picture. The other half is that a closure is a manufactured object with a long processing history before it ever meets a drug product, and much of the material engineering is about surviving that history without changing.

1. Compounding and moulding — The formulation is mixed, sheeted, and compression- or injection-moulded into stoppers. Cure state has to be tight and reproducible, because under-cure raises extractables and over-cure costs elasticity
2. Trimming and washing — Flash removal, then multi-stage washing to reduce particulates and surface residues to the levels the filling line requires
3. Siliconisation — A controlled silicone treatment reduces stopper-to-stopper tack and improves flow through the feeding bowl. The amount is a specification, not an incidental process detail
4. Sterilisation — Typically steam autoclaving or gamma irradiation. Both are ageing processes for an elastomer, and the formulation must be dimensionally and chemically stable through them
5. Ready-to-use supply — Many closures are supplied washed, siliconised, sterilised, and double-bagged so the fill-finish site can use them directly

Several material properties then govern how the closure behaves in service, and they pull against one another in the way that makes any real formulation a compromise:

• Hardness versus resealing — A harder compound gives better machinability and dimensional stability but reseals less reliably after multiple needle penetrations. Softer compounds reseal well but deform more under crimp load
• Compression set — The stopper is held compressed under an aluminium seal for the whole shelf life. A formulation with high compression set gradually relaxes, and the sealing force that maintains CCI decays with it
• Low-temperature elasticity — Critical for lyophilisation and for cold-chain products, where a stopper that stiffens excessively can compromise the seal at the moment it matters
• Coring behaviour — Governed by hardness, surface geometry, and the septum design as much as by the polymer itself
• Moisture uptake and outgassing — Stoppers are dried before use precisely because residual moisture in the rubber can transfer into a lyophilised cake over shelf life

Finally, qualification. In general terms a closure system is evaluated as a system — this stopper design, this glass vial, this crimp, this process — through physicochemical and biological testing of the material, functional testing of penetrability and fragmentation, extractables and leachables studies scaled to the route of administration, and container closure integrity testing on the assembled unit. Stability data on the actual drug product then confirms the whole thing over time. No material claim substitutes for that work, which is why closure suppliers to the pharmaceutical industry operate under quality systems specific to that sector.

For industrial sealing programmes where long-term gas and moisture barrier performance is the requirement, Garmy formulates butyl compound to specification under IATF 16949, ISO 9001, and ISO 14001.

Q: Why is butyl rubber preferred over natural rubber for vial stoppers?

A: Two reasons dominate. First, barrier performance — butyl's crowded, saturated polyisobutylene backbone leaves very little free volume, so oxygen and water vapour permeate far more slowly than through natural rubber. Second, the extractables profile — natural rubber carries protein content and generally requires a heavier cure and antioxidant package, both of which raise the risk of leachables in an injectable product. Natural rubber has been progressively displaced from parenteral closures for these reasons.

Q: What does container closure integrity actually depend on?

A: On the whole system, not just the rubber: the flatness and finish of the vial sealing surface, the stopper geometry and hardness, the crimp force applied to the aluminium seal, and the compression set behaviour of the elastomer over shelf life. The polymer sets the permeation ceiling; the mechanical design and the retained sealing force determine how much of that ceiling is realised. This is why CCI is tested on assembled units rather than inferred from material data.

Q: Why are lyophilisation stoppers a special case?

A: Because they experience the whole freeze-drying cycle before they are seated. The stopper is partially inserted, sits at very low temperature under deep vacuum while the cycle runs, must not outgas into the chamber, and must still be elastic enough to seal when the shelf pushes it home at the end. It then has to keep water vapour out of a hygroscopic cake for the full shelf life. Butyl's combination of low permeability and retained low-temperature elasticity is what makes it suitable.

Q: Does Garmy supply rubber for pharmaceutical closures, and do you hold pharmaceutical certifications?

A: No. Garmy manufactures butyl compound and butyl tape for industrial sealing, construction waterproofing, and automotive NVH applications. We do not produce pharmaceutical closures and we hold no pharmaceutical or medical-device certifications — our quality systems are IATF 16949, ISO 9001, and ISO 14001, which are industrial and automotive in scope. This article is written to explain the material science, not to offer a pharmaceutical-grade product.

Q: Where does the same barrier mechanism apply in industrial sealing?

A: Anywhere a joint has to stop the slow migration of gas or moisture for years: insulating glass edge seals, automotive headlamp and tail lamp housings, electrical enclosures and cable joints, HVAC ductwork, and building envelope joints. Garmy has produced butyl compound since 1999 at our 4,200 m² plant in Eumseong, Chungbuk, Korea, with annual output above 3,400 tonnes and three registered patents. Grades HY-1, HY-2, CN-1, CN-FR, SD-1, and S-3 cover a service range of −40°C to +120°C, with batch certificates of analysis and custom formulation available.

Ready to source the right butyl material for your application?